Abstract
Bladder cancer is the most common malignancy of the urinary tract. The primary standard treatment of the bladder tumors is transurethral resection (TUR), however the percentage of relapse in patients treated with TUR only is up to 70%, and the percentage of tumor progression (invasion of muscle layer) is about 30%. In these patients radical surgical treatment is indicated. Intravesical Bacillus Calmette-Guerin (BCG) installation after TUR of bladder tumors is the most effective support treatment of superficial bladder cancers. The aim of our study was to compare treatment outcomes of patients undergoing TUR to patients treated with combined therapy (BCG immunotherapy after TUR). Results presented in this paper are extracted results of a prospective - retrospective study which is carried out and ongoing at Urology department in Clinical Hospitel Zemun since January 2013.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
